# Follistatin 344 — Research Peptide Profile

> Blocks myostatin and activin — transgenic mice gained 194–327% muscle mass, and a Becker MD trial improved 6-minute walk 11.5%. Gene therapy data.

Source: https://peptpedia.org/peptide/follistatin-344 | Published: 2026-02-13 | Last updated: 2026-07-22

Follistatin 344 is a variant of the natural myostatin-blocking protein — it removes the brakes on muscle growth. Animal data is dramatic; human evidence is early-stage gene-therapy trials in muscular dystrophy, not healthy-muscle enhancement. It remains firmly investigational.

## Overview

Follistatin 344 is a 344-amino acid isoform of the follistatin protein, a critical regulator of muscle mass and reproductive physiology. Processed in vivo to the circulating FS-315 isoform, it gained prominence when transgenic mice overexpressing it showed 194–327% increases in muscle mass. Unlike myostatin-only inhibitors, follistatin simultaneously neutralizes activin A and other TGF-beta ligands, producing greater hypertrophy. The FS-344 isoform is preferred in research for its lower pituitary activin affinity, reducing reproductive hormone disruption.

## Molecular Profile

- **Category:** growth-factors
- **Molecular formula:** C1218H1893N345O370S19
- **Molecular weight:** ~38 kDa
- **CAS number:** 80449-31-6
- **Also known as:** FS-344, FST344, Follistatin
- **Half-life:** Recombinant follistatin protein: approximately 2-4 hours in circulation; gene therapy expression: sustained over months to years
- **Solubility:** Soluble in aqueous buffers at physiological pH
- **Storage:** Store lyophilized protein at -20°C to -80°C. Reconstituted solution at 4°C for short-term use. Avoid repeated freeze-thaw cycles.

## Mechanism of Action

Follistatin 344 exerts its muscle-promoting effects primarily through high-affinity binding and neutralization of myostatin (GDF-8) and activin A, two TGF-beta superfamily ligands that act as negative regulators of skeletal muscle mass. By sequestering these ligands in the extracellular space, follistatin prevents their binding to the activin type IIB receptor (ActRIIB), thereby blocking downstream Smad2/3 phosphorylation and transcriptional suppression of muscle growth genes. Additionally, follistatin promotes satellite cell proliferation and differentiation, increasing the pool of myogenic progenitor cells available for muscle fiber hypertrophy and hyperplasia. Research in nonhuman primates has demonstrated that AAV1-mediated delivery of FS-344 produces durable increases in muscle size and strength persisting for over 15 months, with the transgene expression remaining localized to muscle tissue without systemic hormonal disruption.

## Key Research Findings

- Transgenic mice overexpressing follistatin show 194-327% increases in muscle mass, substantially exceeding the approximately 100% increase from myostatin knockout alone due to simultaneous activin A inhibition.
- A Phase 1/2a clinical trial in Becker muscular dystrophy demonstrated an average 11.5% improvement in six-minute walk test at 6 months (p = 0.02) with AAV1-FS344 gene therapy.
- In nonhuman primates, AAV1-FS344 produced durable muscle hypertrophy lasting over 15 months with no disruption to reproductive hormones or cardiac tissue.
- The FS-344 isoform was selected for clinical development because it has approximately 10-fold lower affinity for pituitary activin compared to FS-288, minimizing reproductive hormone disruption.

## Dosing Information (Research Context)

In gene therapy clinical trials, AAV1-FS344 has been delivered by direct intramuscular injection at doses of 3 x 10^11 to 6 x 10^11 vector genomes per kilogram. Recombinant follistatin protein has been studied in animal models at varying doses. Researchers should consult original trial protocols for specific experimental conditions.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Intramuscular (AAV1-FS344 gene therapy – Phase 1/2a) | 3×10¹¹ – 6×10¹¹ vg/kg | Single injection | Direct intramuscular injection to quadriceps; gene therapy, not conventional peptide dosing |
| Recombinant protein (preclinical only) | Not established in humans | N/A | Animal models only; pharmacokinetic short half-life (~2–4 hours) precludes practical protein administration |

## Researched Effects

- **Muscle Hypertrophy & Strength** (evidence: extensive): Follistatin 344 has been demonstrated to produce pronounced skeletal muscle hypertrophy through simultaneous inhibition of myostatin and activin A signaling via the ActRIIB receptor pathway. Transgenic mouse studies have documented muscle mass increases of 194-327% compared to wild-type controls, with effects exceeding those seen with myostatin knockout alone. In nonhuman primates, AAV1-FS344 intramuscular injection produced significant and durable increases in quadriceps muscle size and strength that persisted for over 15 months without plateau. The mechanism involves both myofiber hypertrophy (increased cross-sectional area of existing fibers) and satellite cell-mediated hyperplasia (formation of new muscle fibers). Research indicates that follistatin's dual blockade of myostatin and activin produces approximately 25-30% greater muscle mass increases compared to myostatin inhibition alone, highlighting the contribution of activin A suppression to the overall anabolic response.
- **Muscular Dystrophy Therapeutic Potential** (evidence: moderate): A Phase 1/2a clinical trial (NCT01519349) demonstrated that AAV1-FS344 gene therapy delivered by intramuscular injection to the quadriceps of patients with Becker muscular dystrophy produced measurable improvements in ambulation and muscle pathology. In the high-dose cohort, two patients improved their six-minute walk test distances by 108 meters and 29 meters respectively, representing clinically meaningful functional gains. Histological analysis of muscle biopsies revealed reduced fibrosis (35-43% of baseline levels), normalized fiber size distribution, and evidence of muscle hypertrophy. The treatment demonstrated a favorable safety profile with no serious adverse events over the 24-month follow-up period. Pooled analysis showed an average 11.5% improvement in six-minute walk test performance at 6 months (p = 0.02), with the degree of pre-existing fibrosis correlating inversely with treatment response.
- **Anti-Fibrotic Effects** (evidence: moderate): Research demonstrates that follistatin 344 significantly reduces pathological fibrosis in skeletal muscle tissue, particularly in the context of muscular dystrophy models. In mdx mice (a model for Duchenne muscular dystrophy), transgenic follistatin expression reduced endomysial and perimysial fibrosis while simultaneously increasing functional muscle mass. The anti-fibrotic mechanism involves suppression of activin A-mediated signaling, which normally promotes fibroblast activation and collagen deposition in damaged muscle. Clinical biopsy data from Becker muscular dystrophy patients treated with AAV1-FS344 confirmed reduced fibrotic tissue content, with quantitative histomorphometry showing fibrosis levels decreasing to 35-43% of pre-treatment values. These findings suggest that follistatin may address both the primary muscle wasting and the secondary fibrotic replacement that characterizes progressive muscular dystrophies.
- **Reproductive Physiology Modulation** (evidence: preliminary): Follistatin plays an established role in regulating reproductive function through its interaction with activin in the hypothalamic-pituitary-gonadal axis. The FS-344 isoform was specifically selected for muscle therapy research because it demonstrates approximately 10-fold lower affinity for pituitary activin compared to the FS-288 isoform, minimizing disruption to FSH secretion and reproductive hormone balance. Primate studies with AAV1-FS344 confirmed that serum estradiol, testosterone, LH, and FSH levels remained within normal physiological ranges throughout 15 months of treatment. However, the broader follistatin family remains under investigation for potential applications in reproductive medicine, including polycystic ovary syndrome and fertility regulation. The differential tissue distribution and activin-binding properties of follistatin isoforms continue to inform the development of muscle-targeted therapies with minimal off-target reproductive effects.
- **Metabolic Regulation** (evidence: preliminary): Emerging research suggests that follistatin may influence metabolic homeostasis beyond its established role in muscle biology. Studies in animal models have demonstrated that increased muscle mass resulting from follistatin overexpression is associated with improved insulin sensitivity and glucose disposal, consistent with the metabolic benefits of increased lean body mass. Follistatin has been shown to modulate brown adipose tissue thermogenesis through interactions with activin and myostatin signaling in adipocytes, potentially influencing energy expenditure and fat metabolism. Research has identified circulating follistatin as an exercise-responsive factor, with plasma levels increasing acutely following resistance exercise, suggesting a role as a myokine that communicates muscle metabolic status to other tissues. These metabolic effects position follistatin at the intersection of muscle biology and whole-body energy regulation.

## Research Applications

- Muscular Dystrophy Gene Therapy
- Muscle Wasting Research
- Sarcopenia Studies
- Reproductive Biology
- TGF-beta Signaling Research

## Key Studies

### A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy

Mendell JR, Sahenk Z, Malik V, et al. — *Molecular Therapy* (2015) — [PMID 25322757](https://pubmed.ncbi.nlm.nih.gov/25322757/) | [doi:10.1038/mt.2014.200](https://doi.org/10.1038/mt.2014.200)

This landmark Phase 1/2a clinical trial evaluated the safety and preliminary efficacy of AAV1-FS344 gene therapy in six patients with Becker muscular dystrophy, divided into low-dose and high-dose cohorts receiving intramuscular injections to the quadriceps. The high-dose cohort demonstrated clinically meaningful improvements, with two patients improving their six-minute walk test distances by 108 meters and 29 meters respectively over the study period. Histological analysis of post-treatment muscle biopsies revealed significant reductions in endomysial fibrosis to 35-43% of baseline levels, accompanied by normalized muscle fiber size distribution and evidence of myofiber hypertrophy. The treatment was well tolerated with no serious adverse events or immune-mediated toxicities observed during the follow-up period. Immunohistochemistry confirmed sustained transgene expression in treated muscles without evidence of cellular immune responses against the follistatin protein. This trial established the first clinical proof-of-concept for follistatin gene therapy in human muscular dystrophy.

### Follistatin gene therapy improves ambulation in Becker muscular dystrophy

Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR — *Journal of Neuromuscular Diseases* (2015) — [PMID 27858738](https://pubmed.ncbi.nlm.nih.gov/27858738/) | [doi:10.3233/JND-150083](https://doi.org/10.3233/JND-150083)

This review examines follistatin gene therapy as a strategy for Becker muscular dystrophy, describing the therapeutic rationale and isoform selection. The authors note that follistatin is a secretory propeptide that potently inhibits the myostatin pathway, increasing skeletal muscle mass, but that its interaction with the pituitary activin-inhibin axis and suppression of follicle-stimulating hormone (FSH) called for caution in clinical use. This limitation was circumvented by using the alternatively spliced variant FS344, which undergoes post-translational modification to FS315; this serum-based isoform has a 10-fold lower affinity for activin than FS288. The review reports that preclinical intramuscular delivery of the follistatin gene demonstrated safety and efficacy in enhancing muscle mass, and it summarizes the results of the first clinical gene transfer trial using the FS344 isoform in subjects with Becker muscular dystrophy, along with future directions for follistatin gene therapy trials.

### Follistatin gene delivery enhances muscle growth and strength in nonhuman primates

Kota J, Handy CR, Haidet AM, et al. — *Science Translational Medicine* (2009) — [PMID 20368179](https://pubmed.ncbi.nlm.nih.gov/20368179/) | [doi:10.1126/scitranslmed.3000112](https://doi.org/10.1126/scitranslmed.3000112)

This pivotal preclinical study demonstrated that AAV1-mediated delivery of follistatin 344 to cynomolgus macaque monkeys produced pronounced and durable increases in muscle size and strength that persisted for over 15 months. Intramuscular injection of AAV1-FS344 into the quadriceps resulted in significant muscle hypertrophy measurable by MRI volumetric analysis, with the CMV promoter producing greater transgene expression and larger muscle size gains compared to the MCK muscle-specific promoter. Comprehensive safety evaluation revealed no abnormal changes in morphology or function of key organs including heart, liver, kidneys, and reproductive tissues. Critically, serum estradiol, testosterone, luteinizing hormone, and follicle-stimulating hormone remained at baseline levels throughout the 15-month observation period, confirming the FS-344 isoform's favorable safety profile regarding reproductive hormone regulation. No evidence of cardiac hypertrophy or systemic immune responses against the follistatin transgene was observed. These primate data provided the essential safety and efficacy foundation that justified subsequent human clinical trials in Becker muscular dystrophy.

### Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease

Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR — *Muscle & Nerve* (2009) — [PMID 19208403](https://pubmed.ncbi.nlm.nih.gov/19208403/) | [doi:10.1002/mus.21244](https://doi.org/10.1002/mus.21244)

This review argued that inhibiting the myostatin pathway offers an alternative strategy for genetic and acquired muscle disorders, such as sporadic inclusion body myositis, where conventional pharmacologic approaches have produced only modest clinical benefits. The authors highlighted follistatin as a powerful antagonist of myostatin capable of increasing muscle mass and strength, while noting that follistatin's origin in the ovary and its suppression of follicle-stimulating hormone raise concerns about adverse effects on the hypothalamic-pituitary-gonadal axis and reproductive capabilities. To bypass these off-target effects, they described delivering an alternatively spliced follistatin cDNA (FS344) by adeno-associated virus (AAV) to muscle; the resulting 315-amino-acid transgene product is secreted from muscle and circulates in serum, thereby avoiding cell-surface binding sites. The authors reported that their translational studies produced increased muscle size and strength in species ranging from mice to monkeys, with adverse effects avoided and no organ-system pathology or change in reproductive capabilities observed. They concluded that these findings provide the impetus to advance toward gene therapy clinical trials delivering AAV-FS344 to increase muscle size and function in patients with neuromuscular disease.

### Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP — *American Journal of Physiology-Endocrinology and Metabolism* (2009) — [PMID 19435857](https://pubmed.ncbi.nlm.nih.gov/19435857/) | [doi:10.1152/ajpendo.00193.2009](https://doi.org/10.1152/ajpendo.00193.2009)

This mechanistic study elucidated the cellular pathways through which follistatin promotes skeletal muscle hypertrophy, demonstrating that the effect involves both myofiber hypertrophy and satellite cell-mediated hyperplasia. Using electroporation-mediated follistatin overexpression in mouse tibialis anterior muscles, researchers showed a 30% increase in muscle mass within two weeks, accompanied by a significant increase in myofiber cross-sectional area. BrdU incorporation experiments revealed enhanced satellite cell proliferation in follistatin-treated muscles, indicating activation of the muscle stem cell compartment as a key component of the hypertrophic response. The study demonstrated that follistatin inhibited both myostatin and activin A signaling through the ActRIIB-Smad2/3 pathway, and that dual inhibition was required for the full magnitude of the hypertrophic effect. Quantitative analysis showed that follistatin-mediated muscle growth exceeded that achievable by myostatin inhibition alone by approximately 25-30%, directly attributable to the additional suppression of activin A signaling. These findings established the dual-ligand inhibition model that subsequently informed the design of clinical follistatin gene therapy programs.

## Frequently Asked Questions

### What is the difference between Follistatin 344 and Follistatin 288?

Both isoforms are generated from the same gene by alternative splicing, differing in the C-terminal domain. FS-288 has a high-affinity heparan sulfate binding domain that causes it to bind tightly to cell surface proteoglycans—making it locally acting with very high affinity for pituitary activin receptors, posing reproductive hormone disruption risk. FS-344 is processed in vivo to FS-315 (the main circulating form) by removal of its acidic C-terminal tail. FS-315 has approximately 10-fold lower pituitary activin affinity than FS-288, making it the preferred clinical isoform—retained muscle activity without disrupting FSH/LH secretion. This isoform selectivity was confirmed in primate studies over 15 months where FS-344-treated animals maintained normal sex hormone levels.

### How does Follistatin 344 compare to direct myostatin inhibitors?

Follistatin 344 is more potent than myostatin-specific inhibitors because it simultaneously blocks both myostatin (GDF-8) and activin A, which both signal through the ActRIIB receptor to suppress muscle growth via Smad2/3 phosphorylation. Transgenic data: follistatin overexpression → 194–327% muscle mass increase; myostatin knockout alone → approximately 100% increase. The additional ~100–200% from follistatin is attributed to activin A blockade. Drugs targeting only myostatin (e.g., landogrozumab, anti-myostatin antibodies) have consistently underperformed in clinical trials, while follistatin-based approaches show greater preclinical efficacy—likely because activin A is an equally important negative regulator of muscle mass that purely anti-myostatin therapies miss.

### What has clinical research shown about Follistatin 344 gene therapy?

The NCT01519349 Phase 1/2a trial in 6 Becker muscular dystrophy patients showed: high-dose cohort 6MWT improvement of +108 m and +29 m in two patients; average 11.5% improvement in 6MWT at 6 months (p=0.02); fibrosis reduced to 35–43% of baseline on biopsy; no serious adverse events; normal reproductive hormone levels throughout. Limitations: very small n=6; open-label; no control group. This provides proof-of-concept for the approach but is insufficient for regulatory approval. Larger Phase 2b/3 trials would be needed—none have been announced as of 2026, partly because commercial gene therapy programs are competing with exon-skipping and antisense approaches (e.g., eteplirsen) for DMD/BMD development resources.

### Is Follistatin 344 used in competitive sports research?

Follistatin 344 injection has been reported as a performance-enhancing substance in some elite athletic circles, prompting anti-doping research. The World Anti-Doping Agency (WADA) includes follistatin-derived peptides on its Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). Detection methods include serum follistatin immunoassays and biomarker panels for myostatin pathway suppression (reduced serum myostatin, elevated follistatin:myostatin ratio). Recombinant follistatin protein has been misused as a self-administered injection. The research community and WADA collaborate on detection methods, though confirmation in well-controlled human studies of illicit use is limited.

### Why has Follistatin 344 shown greater muscle effects than pure myostatin inhibitors in clinical trials?

Myostatin-specific antibodies (e.g., landogrozumab, domagrozumab) have consistently disappointed in clinical trials for muscular dystrophy and sarcopenia—achieving only 2–5% muscle mass gains despite strong myostatin inhibition. The explanation is that myostatin blockade triggers compensatory upregulation of activin A (a related TGF-β family member that also suppresses muscle via ActRIIB). Follistatin 344 simultaneously neutralizes both myostatin and activin A—blocking both brakes on muscle growth simultaneously. This dual block produces additive or synergistic muscle growth compared to targeting either alone. This mechanistic insight led to clinical development of bimagrumab (anti-ActRIIB antibody) which, like follistatin, blocks both ligands at the receptor level and shows superior efficacy.

### What is the mechanism of Follistatin 344 in polycystic ovary syndrome (PCOS)?

Follistatin regulates reproductive function by neutralizing activins in the pituitary—activin A stimulates FSH secretion. Physiological follistatin modulates the FSH pulse. In PCOS, an imbalance exists: elevated intraovarian activin activity contributes to follicular arrest, androgen excess, and ovulatory dysfunction. Circulating follistatin levels in PCOS are elevated as a compensatory response but are insufficient to normalize intraovarian activin activity. Gene therapy with Follistatin 344 in PCOS primate models reduced LH levels, improved ovarian morphology, and reduced androgen levels—suggesting potential as a therapeutic approach. These findings are preclinical only; no human PCOS trials have been conducted.

### What are the main mechanisms by which Follistatin 344 supports bone health?

Activin A (which follistatin neutralizes) is a potent suppressor of bone formation: it inhibits osteoblast differentiation while promoting osteoclast activity. Follistatin 344, by blocking activin A, removes this brake on bone formation and simultaneously reduces osteoclast-mediated bone resorption. In preclinical osteoporosis models (ovariectomized rodents), follistatin gene therapy increased bone mineral density by 15–25% and improved bone strength parameters. This dual anabolic/anti-catabolic mechanism on bone is distinct from existing osteoporosis therapies (bisphosphonates reduce resorption; teriparatide increases formation). The combined muscle and bone effects make follistatin particularly attractive for sarco-osteoporosis—the simultaneous muscle and bone loss of aging.

### How is recombinant Follistatin 344 protein different from AAV-delivered Follistatin 344?

These are fundamentally different delivery approaches. Recombinant Follistatin 344 protein (rFST344) is produced in CHO or HEK cells, purified, and administered as a repeated injection—with the same rapid clearance limitations as other proteins (plasma half-life approximately 40 minutes; cleared by liver and kidney). AAV-Follistatin 344 gene therapy uses a recombinant adeno-associated virus vector carrying the FS344 gene—injected intramuscularly, where AAV transfects muscle cells and causes them to produce follistatin continuously without further dosing (potential for lifelong expression from a single treatment). The gene therapy approach is the one used in clinical trials for muscular dystrophy; the protein injection approach is primarily used in research settings.

## Related Peptides

- [GHK-Cu](https://peptpedia.org/peptide/ghk-cu)
- [IGF-1 LR3](https://peptpedia.org/peptide/igf-1-lr3)
- [TB-500](https://peptpedia.org/peptide/tb-500)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org